Drugs / MB-CART-19
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1 | NCT03434769 | Jul 2018 → Mar 2023 overdue | non-Hodgkin lymphoma | Benjamin Tomlinson | Active not recruiting | No outcome recorded |
Evidence & citations 2 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | MB-CART-19 | “MB-CART-19 is an anti-CD19 CAR T-cell product manufactured using the CliniMACS Prodigy device with 4-1BB and CD3ζ costimulatory domains.” PMID 40115173 ↗ Mar 2025 |
| Modality | Cell therapy | “MB-CART-19 is an anti-CD19 CAR T-cell product” PMID 40115173 ↗ Mar 2025 |